Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Trading update

19 Jan 2011 07:00

RNS Number : 6952Z
Cello Group plc
19 January 2011
 



19 January 2011

 

Cello Group plc

Pre-close trading update - year ended 31 December 2010

 

Cello Group plc (AIM: CLL, 'the Group'), the insight and strategic marketing group, today publishes the following pre-close trading update for the year ended 31 December 2010.

 

Summary

 

The Group has experienced strong profit growth backed by strong cash conversion. The Board expects that full-year headline pre-tax profits will be ahead of expectations and net debt will be better than expected at less than £9.0m.

 

Operating performance

 

Research and Consulting

 

The Group's market research and consulting business has experienced a strong second half, with robust like-for-like revenue growth. Operating profits are expected to have risen by more than 20% on a like-for-like annual basis, reflecting continued strong spending patterns from the Group's broad, international blue-chip client base, and improving operating margins.

 

Performance has been particularly strong in the pharmaceutical and health related client sectors, which now constitute the primary area of the Group's research and consulting activity and which operate at a higher margin than the Group's other client sectors.

 

Non-UK revenues are growing faster than UK revenues and now comprise almost half of the Group's research and consulting activity. In particular, the Group's pharmaceutical offering based in the New York office has performed very strongly and is expanding rapidly. In addition, following significant blue-chip client wins in 2010, the Group intends to expand its US West Coast office more aggressively in 2011.

 

As indicated in the Group's interim results, which were announced on 14 September 2010, the Group has incurred an exceptional charge of approximately £0.8m relating to the material reduction of the Group's exposure to public sector client spend. This process is now complete.

 

Notable project wins in the research and consulting area came from our long established blue chip client list and include Nokia, TFL, News International, EBay, MTV, Travis Perkins, Adidas, Kellogg's, KPMG, P&G, HP, RIM, PWC, Pfizer, Novartis, Novo Nordisk, Eurostar, GSK Global, Unilever, 3M, Visa, Wrigleys, BUPA, RBS, Citi and Nestle.

 

Tangible

 

Tangible's developing position in web-based social media research and communications has continued to benefit the network, as well as the Group's overall research offering. Approximately 20% of Tangible's activity is now in the research and consulting area, a transition which the Group anticipates continuing rapidly in 2011.

 

Tangible has delivered a solid result, against the headwind of UK public sector marketing cuts. The Board anticipates that, whilst revenues have declined year on year reflecting the reduction in public sector spend, profits will have grown by more than 10% with improved margins driven by good cost management.

 

International revenues in Tangible have grown in 2010, with some significant new client wins. Tangible is opening an office in Beijing which may also serve as a hub for the research and consulting business. We continue to appraise expansion options in the Asia-Pacific region.

 

Notable new business wins by Tangible came from both the commercial and charity sectors, and include Ben & Jerry's, Dettol, O2, Pfizer, Dove, IFAW, SPX, First Great Western, NHS, Tesco Bank, Cancer Research UK, British Red Cross, Sony, Royal Mail, Scottish & Southern Energy, Sainsbury's Finance, Scottish Government, Nestle Purina, Macmillan Cancer Support, Salvation Army and the Stroke Association.

 

Net debt

 

Net debt for the year end will be better than expected, having fallen below £9.0m, reflecting strong cash flow conversion. The Group's overall debt facilities stand at £17.0m, providing financial flexibility and giving the Group scope to prudently expand as appropriate.

 

Outlook

 

Revenue momentum experienced in the research and consulting business in the last quarter of 2010 means that the Group is carrying forward a healthy pipeline of activity into the first quarter of 2011. At this early stage of the year, the Group is currently trading in line with management's expectations. The Board remains optimistic for the prospects in 2011.

 

The Group expects to announce its preliminary results for the year ended 31 December 2010 on Wednesday 15 March 2011.

 

Enquiries:

 

Cello Group plc

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Altium

Ben Thorne

020 7484 4040

College Hill

Kay Larsen/Rozi Morris

020 7457 2020

 

 

Notes to Editors

 

Cello is an insight and strategic marketing group. The Group's strategy is to create value for shareholders by building an international research and consulting business able to advise blue-chip clients globally, along with a marketing business capable of delivering world class solutions.

 

Cello has annualised revenue in excess of £125m, annualised operating income in excess of £60m and employs just under 800 professional staff.

 

www.cellogroup.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXFPFAPFEFF
Date   Source Headline
2nd Oct 20198:40 amRNSDisposal
18th Sep 20197:00 amRNSInterim Results
23rd Aug 201910:40 amRNSHolding(s) in Company
16th Aug 20197:00 amRNSAcquisition of ISS
6th Aug 20193:07 pmRNSTotal Voting Rights
6th Aug 20197:00 amRNSNotification of Half Year Results
18th Jul 20197:00 amRNSPre-close Trading Update
20th Jun 20194:29 pmRNSDirector/PDMR Shareholding
10th Jun 20199:41 amRNSTotal Voting Rights
24th May 201912:45 pmRNSBlock listing Interim Review
20th May 20194:29 pmRNSIssue of Equity
15th May 20197:00 amRNSHolding(s) in Company
8th May 20191:30 pmRNSResult of AGM
8th May 20197:00 amRNSAGM Statement
1st May 201912:15 pmRNSTotal Voting Rights
15th Apr 201911:12 amRNSAnnual Report and Notice of AGM
10th Apr 20197:00 amRNSCapital Markets Event
4th Apr 201910:00 amRNSTotal Voting Rights
27th Mar 20191:00 pmRNSHolding(s) in Company
21st Mar 20193:10 pmRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSPreliminary Results
6th Mar 20191:51 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSNotice of Full Year Results
17th Jan 20197:00 amRNSPre-Close Trading Statement
14th Dec 20189:24 amRNSBlock Listing Update
23rd Nov 20183:45 pmRNSHolding(s) in Company
19th Nov 20182:45 pmRNSHolding(s) in Company
12th Nov 201811:30 amRNSDirectorate Change
5th Nov 20182:00 pmRNSDirectorate Change
31st Oct 20183:30 pmRNSDirector/PDMR Shareholding
10th Oct 20187:00 amRNSDirector/PDMR Shareholding
2nd Oct 20187:00 amRNSAppointment of Executive Director
25th Sep 20181:00 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 201811:39 amRNSTransfer of FTSE classification to Healthcare
21st Sep 201810:15 amRNSDirector/PDMR Shareholding
20th Sep 20184:00 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSDirector/PDMR Shareholding
19th Sep 20187:00 amRNSInterim Results
22nd Aug 20181:51 pmRNSHolding(s) in Company
17th Aug 20187:00 amRNSNotification of Half Year Results
16th Aug 20182:00 pmRNSTotal Voting Rights
16th Aug 20181:30 pmRNSBoard Changes
23rd Jul 20187:00 amRNSHolding(s) in Company
19th Jul 20187:00 amRNSPre-close Trading Update
17th Jul 20187:00 amRNSChange of registered office
4th Jul 20181:53 pmRNSHolding(s) in Company
27th Jun 201812:46 pmRNSHolding(s) in Company
22nd Jun 20184:47 pmRNSHolding(s) in Company
20th Jun 20182:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.